Sign In
Buy STXS
$1.84
-0.130 (-6.60%)
At Close: Jun 03, 2026
Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025
05:03am, Monday, 02'nd Dec 2024
MAGiC is set to receive the CE Mark by early 2025. Tenders will be completed by Q2 or Q3 2025; the FDA approval timeline is similar. The APT acquisition allowed Stereotaxis to complete the manufacturi
STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System
12:10pm, Tuesday, 26'th Nov 2024
Stereotaxis, in collaboration with MicroPort EP, announces the receipt of NMPA approval for its Genesis RMN System.
Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference
08:28am, Tuesday, 26'th Nov 2024
ST. LOUIS, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fis
Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China
08:21am, Monday, 25'th Nov 2024
ST. LOUIS and SHANGHAI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP”), today announced regulatory approval of t
Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System
08:18am, Wednesday, 20'th Nov 2024
ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physician
Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript
07:03pm, Monday, 11'th Nov 2024
Stereotaxis, Inc. (NYSE:STXS ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants David Fischel - Chairman and Chief Executive Officer Kimberly Peery - Chief Financial
Stereotaxis Inc. (STXS) Reports Q3 Loss, Tops Revenue Estimates
06:11pm, Monday, 11'th Nov 2024
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago.
Stereotaxis Reports 2024 Third Quarter Financial Results
04:02pm, Monday, 11'th Nov 2024
ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul
Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation
08:41am, Monday, 21'st Oct 2024
ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will p
Stereotaxis to Present at Upcoming Investor Conferences
08:40am, Monday, 09'th Sep 2024
ST. LOUIS, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fi
Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society's HRX Congress
08:53am, Tuesday, 03'rd Sep 2024
ST. LOUIS, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its tech
Stereotaxis Receives CE Mark For GenesisX, Nears MAGiC Approval
07:22pm, Sunday, 25'th Aug 2024
GenesisX was approved in Europe and is set to be approved in the US late this year. The new robot is a giant leap forward in accessibility. Stereotaxis should get MAGiC approved in Europe in October.
Stereotaxis (STXS) Achieves CE Mark in Europe for GenesisX
10:20am, Thursday, 15'th Aug 2024
Stereotaxis (STXS) gets a CE mark in Europe for its GenesisX robotic system. Following this, the company also submits a 501(k) application for FDA clearance.
Stereotaxis (STXS) Receives European Approval for GenesisX
10:16am, Thursday, 15'th Aug 2024
Stereotaxis (STXS) gains CE mark for GenesisX and plans to launch the system in 2025.
Stereotaxis, Inc. (STXS) Q2 2024 Earnings Call Transcript
11:33pm, Monday, 12'th Aug 2024
Stereotaxis, Inc. (NYSE:STXS ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kimberly Peery - CFO Conference Call Participants Adam
